FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2443265418> ?p ?o ?g. }

• W2443265418 endingPage "368" @default.
• W2443265418 startingPage "364" @default.
• W2443265418 abstract "In this phase II study, 41 patients with locally advanced urothelial bladder cancer (T2-4, NO, MO) were treated with primary chemotherapy (cisplatin, epirubicin, methotrexate: PEM-3). All the patients were assessable for response and toxicity. Clinical monitoring was performed with computerized tomography and cystoscopy. Nineteen clinical complete remissions (46%) and 10 partial remissions (24.5%) were obtained (CR + PR, 70.5%; 95% confidence interval, 57%-85%). Ten patients were considered to have clinically stable disease (24.5%), and 2 patients progressed (5%). Surgery after chemotherapy was performed in 22 cases: in 6 patients (27%) a pathologic complete response was achieved. The pathologic stage was lower than the initial clinical stage in 13 patients (59%). After a median follow-up of 3 years (range, 1-4), the median time to progression was 104 weeks. At this writing, 20 patients, 12 of which were submitted to surgery and 8 were not operated, are disease-free. The 3-year survival rate is 52%. No one had to interrupt the treatment because of toxicity. In conclusion, the PEM-3 regimen is a very active and well-tolerated regimen in locally advanced bladder cancer." @default.
• W2443265418 created "2016-06-24" @default.
• W2443265418 creator A5018118709 @default.
• W2443265418 creator A5022077666 @default.
• W2443265418 creator A5025307558 @default.
• W2443265418 creator A5028748860 @default.
• W2443265418 creator A5029160570 @default.
• W2443265418 creator A5031731104 @default.
• W2443265418 creator A5033030232 @default.
• W2443265418 creator A5038898384 @default.
• W2443265418 creator A5054546157 @default.
• W2443265418 creator A5061553347 @default.
• W2443265418 creator A5062042365 @default.
• W2443265418 creator A5065342572 @default.
• W2443265418 creator A5070644908 @default.
• W2443265418 creator A5072521541 @default.
• W2443265418 creator A5073450182 @default.
• W2443265418 creator A5081963139 @default.
• W2443265418 date "1996-07-01" @default.
• W2443265418 modified "2023-10-11" @default.
• W2443265418 title "A New Regimen of Cisplatin, Epirubicin and Methotrexate (PEM-3) as Primary Chemothfrapy for Locally Advanced Bladder Cancer" @default.
• W2443265418 cites W2011729580 @default.
• W2443265418 cites W2070482456 @default.
• W2443265418 cites W2071772756 @default.
• W2443265418 cites W2119211684 @default.
• W2443265418 cites W2161603073 @default.
• W2443265418 cites W2167805334 @default.
• W2443265418 cites W2168812605 @default.
• W2443265418 cites W2178106439 @default.
• W2443265418 cites W2396846532 @default.
• W2443265418 cites W2410120991 @default.
• W2443265418 cites W2410167743 @default.
• W2443265418 cites W2415307606 @default.
• W2443265418 cites W2416342137 @default.
• W2443265418 cites W2418086207 @default.
• W2443265418 cites W2419382698 @default.
• W2443265418 cites W2474434662 @default.
• W2443265418 cites W2486390096 @default.
• W2443265418 cites W336133924 @default.
• W2443265418 doi "https://doi.org/10.1177/030089169608200413" @default.
• W2443265418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8890971" @default.
• W2443265418 hasPublicationYear "1996" @default.
• W2443265418 type Work @default.
• W2443265418 sameAs 2443265418 @default.
• W2443265418 citedByCount "2" @default.
• W2443265418 crossrefType "journal-article" @default.
• W2443265418 hasAuthorship W2443265418A5018118709 @default.
• W2443265418 hasAuthorship W2443265418A5022077666 @default.
• W2443265418 hasAuthorship W2443265418A5025307558 @default.
• W2443265418 hasAuthorship W2443265418A5028748860 @default.
• W2443265418 hasAuthorship W2443265418A5029160570 @default.
• W2443265418 hasAuthorship W2443265418A5031731104 @default.
• W2443265418 hasAuthorship W2443265418A5033030232 @default.
• W2443265418 hasAuthorship W2443265418A5038898384 @default.
• W2443265418 hasAuthorship W2443265418A5054546157 @default.
• W2443265418 hasAuthorship W2443265418A5061553347 @default.
• W2443265418 hasAuthorship W2443265418A5062042365 @default.
• W2443265418 hasAuthorship W2443265418A5065342572 @default.
• W2443265418 hasAuthorship W2443265418A5070644908 @default.
• W2443265418 hasAuthorship W2443265418A5072521541 @default.
• W2443265418 hasAuthorship W2443265418A5073450182 @default.
• W2443265418 hasAuthorship W2443265418A5081963139 @default.
• W2443265418 hasConcept C121608353 @default.
• W2443265418 hasConcept C126322002 @default.
• W2443265418 hasConcept C126894567 @default.
• W2443265418 hasConcept C141071460 @default.
• W2443265418 hasConcept C143998085 @default.
• W2443265418 hasConcept C2776694085 @default.
• W2443265418 hasConcept C2776755627 @default.
• W2443265418 hasConcept C2778239845 @default.
• W2443265418 hasConcept C2778496288 @default.
• W2443265418 hasConcept C2778822529 @default.
• W2443265418 hasConcept C2780352672 @default.
• W2443265418 hasConcept C2780835546 @default.
• W2443265418 hasConcept C2781059491 @default.
• W2443265418 hasConcept C2781413609 @default.
• W2443265418 hasConcept C31760486 @default.
• W2443265418 hasConcept C71924100 @default.
• W2443265418 hasConcept C90924648 @default.
• W2443265418 hasConceptScore W2443265418C121608353 @default.
• W2443265418 hasConceptScore W2443265418C126322002 @default.
• W2443265418 hasConceptScore W2443265418C126894567 @default.
• W2443265418 hasConceptScore W2443265418C141071460 @default.
• W2443265418 hasConceptScore W2443265418C143998085 @default.
• W2443265418 hasConceptScore W2443265418C2776694085 @default.
• W2443265418 hasConceptScore W2443265418C2776755627 @default.
• W2443265418 hasConceptScore W2443265418C2778239845 @default.
• W2443265418 hasConceptScore W2443265418C2778496288 @default.
• W2443265418 hasConceptScore W2443265418C2778822529 @default.
• W2443265418 hasConceptScore W2443265418C2780352672 @default.
• W2443265418 hasConceptScore W2443265418C2780835546 @default.
• W2443265418 hasConceptScore W2443265418C2781059491 @default.
• W2443265418 hasConceptScore W2443265418C2781413609 @default.
• W2443265418 hasConceptScore W2443265418C31760486 @default.
• W2443265418 hasConceptScore W2443265418C71924100 @default.
• W2443265418 hasConceptScore W2443265418C90924648 @default.
• W2443265418 hasIssue "4" @default.
• W2443265418 hasLocation W24432654181 @default.

• next